Too Many Middlemen? Long-Term Care Pharmacies are Losing Fight for Control of Part D Formularies
This article was originally published in RPM Report
Executive Summary
Omnicare's lawsuit against UnitedHealth Group is part of a battle for survival by long-term care pharmacy providers. The stakes for manufacturers are high: who can really deliver market share under Part D?
You may also be interested in...
Protected Class Lobbying Begin
Bayer is CMS to add multiple sclerosis to the list of drug classes protected from formulary restrictions under the Medicare Part D prescription drug program. The first request to broaden the list of protected classes won't be the last.
Medicare Rx at a Turning Point: Big Plans Stumble as Part D Enters a Pivotal Year
United, Humana and especially WellCare are taking their licks in the run-up to the third year of the Medicare prescription drug program. That is just the latest warning sign for pharma and biotech companies that a critical market is entering a critical turning point.
Medicare Rx at a Turning Point: Big Plans Stumble as Part D Enters a Pivotal Year
United, Humana and especially WellCare are taking their licks in the run-up to the third year of the Medicare prescription drug program. That is just the latest warning sign for pharma and biotech companies that a critical market is entering a critical turning point.